The results of these studies should pave the way for a new era in thyroid cancer therapy, in which the genetic basis of tumor development is used to tailor the best treatment for each patient.

FDA approved for the treatment of metastatic melanoma harboring activating BRAF mutations in August, 2011. Vemurafenib is metabolized by cytochrome P450 isoenzymes (predominantly CYP3A4 ...

The BRAF Inhibitors market is expected to grow significantly in the coming years. This is due to the increasing number of patients being diagnosed with cancer, rise in biomarker testing rates, the ...

Without releasing specific figures, Pfizer said Monday that treatment ... BRAF V600E mutation, which can lead to activation of signaling pathways that drive certain cancers, including colorectal ...

More than 150,000 people are diagnosed with colorectal cancer each year, making it the fourth most common cancer in the U.S., according to the National Cancer Institute. BRAF mutations occur in ...

representing a doubling of the odds of achieving an objective response BRAFTOVI combination regimen is the first and only targeted therapy approved by the U.S. FDA for treatment-naïve patients with ...